TomBAvoider Posted August 23, 2019 Report Share Posted August 23, 2019 A company focused on aging research is conducting trails of a rapamycin analogue with a view to impact on aging in humans - although of course, they need a proxy of some kind, so they picked the immune system. Now, obviously, it's just one subsytem, but at least it is in humans, which should be interesting at least insofar as dosage and protocol are concerned, since we have no guidance in that respect except for the unacceptable original application in organ transplant rejection. Sorely lacking in detail, but here's a blurb: https://www.technologyreview.com/s/614154/the-anti-aging-drug-thats-just-around-the-corner/ Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.